ALEC(ALEC)
ALEC
ANALYST COVERAGE14 analysts
BUY
▼ -5.4%downside to target
PRICE
Prev Close
2.16
Open
2.13
Day Range2.05 – 2.15
2.05
2.15
52W Range1.09 – 3.40
1.09
3.40
44% of range
VOLUME & SIZE
Avg Volume
699.4K
FUNDAMENTALS
P/E Ratio
-1.8x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.65
High vol
TECHNICAL
RSI (14)
50
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 19
DEx-Dividend
In 88 days
Aug 14
PDividend Pay
In 101 days
Aug 27
Key MetricsTTM
Market Cap$233.74M
Revenue TTM$18.42M
Net Income TTM-$125.39M
Free Cash Flow-$173.20M
Gross Margin88.7%
Operating Margin-741.3%
Net Margin-680.8%
Return on Equity-295.2%
Return on Assets-52.3%
Debt / Equity3.33
Current Ratio5.25
EPS TTM$-1.13
ALEC News
About
we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.
Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Arnon Rosenthal
Website
Eric BrownDirector of Antibody Discovery & Protein Engineering
Kristina CutterChief Development Officer
Arnon RosenthalCo-Founder, Chief Executive Officer & Director
Giacomo SalvadoreChief Medical Officer
Neil BerkleyCFO & Chief Business Officer
Katie HoganSenior Director of Corporate Communication & Investor Relations
Danielle PasqualoneGeneral Counsel
Hua Long DABTSenior VP & Head of Research
Clare HuntChief People & Places Officer